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Background: In early-phase trials, a human papillomavirus
16 (HPV16) virus–like particle (VLP) vaccine has been
shown to be well tolerated, immunogenic, and protective
against HPV16 in women, most of whom were taking oral
contraceptives. Previous studies have not determined wheth-
er HPV immunization results in specific antibody levels in
the human genital tract or whether these levels might vary
during contraceptive or ovulatory cycles. Therefore, we de-
termined the levels of total and specific antibodies in the
cervical secretions of women who had been immunized with
HPV16 VLPs and examined the influence of the menstrual
cycle and oral contraceptive use on these levels. Methods:
Two groups of women were immunized, seven who were
taking oral contraceptives and 11 who were ovulating. After
seroconversion, serum and cervical secretions were collected
twice weekly for 5 weeks. Total immunoglobulins (IgG and
IgA) and vaccine-specific IgGs were determined by enzyme-
linked immunosorbent assay. Nonparametric statistical
analyses were used to determine the statistical significance of
differences in IgG levels between groups, and correlations
between serum- and cervical-specific IgG levels were deter-
mined by the Spearman correlation coefficient. Results: All
participants developed detectable titers of anti-HPV16 VLP
IgGs in their cervical secretions after immunization. The
cervical titers of specific IgG and total IgGs and IgAs among
participants in the contraceptive group were relatively con-
stant throughout the contraceptive cycle. In contrast, the
cervical titers of specific IgG and total IgGs and IgAs among
participants in the ovulatory group varied during the men-
strual cycle, being highest during the proliferative phase,
decreasing approximately ninefold around ovulation, and in-
creasing approximately threefold during the luteal phase.
Serum- and cervical-specific IgG levels were correlated
(r = .86) in women in the contraceptive group but not in
women in the ovulatory group (r = .27). Conclusions: The
relatively high titer of anti-HPV16 antibodies at the cervix is
promising in terms of vaccine efficacy; however, the de-
crease in antibody titer around ovulation raises the possibil-
ity that the HPV16 VLP vaccine might be less effective dur-
ing the peri-ovulatory phase. [J Natl Cancer Inst 2003;95:
1128–37]
Protective immunization requires the induction of an effec-
tive immune response at disease-relevant sites, where the pres-
ence of neutralizing antibodies is regarded as a key effector of
many prophylactic vaccines (1). Most approved preventive vac-
cines are administered systemically, including some candidate
vaccines against genital infection with herpes simplex viruses
(HSVs) and human papillomaviruses (HPVs).
Although a mucosal route of immunization can induce the
local production of polymeric secretory immunoglobulin A
(sIgA) in the female genital tract (2), the predominant immuno-
globulin in female genital mucosal secretions is monomeric im-
munoglobulin G (IgG), which is in contrast to the secretions of
most mucosae, which are predominantly sIgA (3–5). The ma-
jority of IgG in the female genital tract probably results from the
transudation of serum antibodies; however, it is possible that
some IgG may be actively transported or locally produced in the
mucosa (6,7). Immunization of rodents via a systemic route has
been shown to lead to vaccine-specific IgG in the female genital
tract (8–10). In addition, systemic immunization (11,12) or pas-
sive transfer of induced serum antibodies (13) can confer pro-
tection against HSV infection in animal models.
Much less is known about the immune response in the human
female genital tract following systemic immunization, although
specific antibody levels achieved at that site are likely to be
related directly to vaccine efficacy. Parenteral immunization
with tetanus toxoid vaccine has been shown to elicit vaccine-
specific IgG in the female genital tract, but negative results were
obtained with parenteral influenza vaccine (14,15). As is the
case in rodents (9,16–18), the overall level of Igs in human
female genital tract secretions is likely to be subject to consid-
erable hormone-dependent variations during the menstrual cycle
(14,19–25). However, no studies involving systemic immuniza-
tion have examined the degree to which the menstrual cycle or
the hormones present in oral contraceptives might affect vac-
cine-specific Igs in the genital tract.
PVs are epitheliotropic viruses whose sites of infection in-
clude the female genital tract (26). Although most genital HPV
infections have a benign outcome, infection with a subset of
HPV types, of which HPV16 is the most common, accounts for
almost all cases of cervical cancer (26), which is the second most
common cause of cancer deaths among women worldwide
(26,27). Cervical cancer remains an important public health con-
cern in industrialized countries despite well-established screen-
ing programs, and it occurs even more frequently in developing
countries than it does in industrialized countries because of the
lack of resources for population-wide screening.
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The main public health goal of an HPV vaccine is to reduce
the incidence of cervical cancer and precancerous lesions by
preventing the establishment of persistent HPV infections that
can lead to this malignancy. Candidate prophylactic HPV vac-
cines currently being tested in human trials are based on the
observation that expression of the PV L1 major capsid protein
leads to self-assembly of virus-like particles (VLPs) that re-
semble authentic virions and contain immunodominant neutral-
ization epitopes [reviewed in (28)]. Animal models of PV in-
fection have shown that parenteral immunization with VLP
vaccines confers protection against challenge by the homolo-
gous virus in two oral mucosal PV models (29,30) and one
cutaneous PV model (31,32). Studies involving passive transfer
of immune IgG have shown that protection against cutaneous or
oral animal PV infection is mediated largely by neutralizing
IgGs. In early-phase human trials, systemic immunization with
candidate L1 VLP vaccines involving HPV16 and other HPV
types has been well tolerated, has induced high titers of neutral-
izing antibodies, and has been protective against HPV16 infec-
tion in women, most of whom were taking oral contraceptives
(33–36). Although the level of specific antibodies in the human
female genital tract is likely to be an important determinant of
vaccine efficacy, previous studies (33–36) have not determined
whether HPV immunization results in specific antibodies in the
human female genital tract or whether these levels might vary
during contraceptive or ovulatory cycles. Therefore, we fol-
lowed healthy adult women who had received parenteral immu-
nization with a candidate HPV L1 VLP vaccine to monitor vac-
cine-specific and total Ig levels in their genital tract during
different phases of ovulatory and contraceptive cycles and ex-
amined the influence of menstrual cycle stage and oral contra-
ceptive use on these levels.
PARTICIPANTS AND METHODS
Participants
Healthy adult women aged 18 to 45 years, with no history of
positive Papanicolaou (Pap) smear, were recruited. Each partici-
pant’s health was confirmed by medical history, serologic tests,
and urinalysis for the presence of leukocytes. Participants un-
derwent a routine gynecologic examination, which included
Thinprep (Cytyc, Boxborough, MA) cervical sampling. Partici-
pants diagnosed with Candida (n  1) or urinary tract infections
(n  2) were treated prior to immunization. Participants were
excluded if they had an abnormal Pap smear (i.e., atypical squa-
mous cytology of undetermined significance [ASCUS] or low-
grade squamous intraepithelial lesions [LSILs]), human immu-
nodeficiency virus seropositivity, HPV16 seropositivity, were
taking chronic medication, were pregnant, or were taking oral
contraceptives other than the estroprogestative Gynera or Minu-
let (0.03 mg of ethinylestradiol and 0.075 mg of gestodene).
For logistical reasons, two separate groups of women were
recruited; the first group followed immunization schedule 1 and
the second group followed immunization schedule 2 (see “Vac-
cine and Immunization Schedule” section below). Following
the screening visit of the first group of participants (n  14),
10 women were enrolled in the study. Four women were ex-
cluded from the study because they had HPV16 IgG titers higher
than 50 (n  2), or their Pap smears indicated the presence of
ASCUS (n  1) or LSILs (n  1). One additional participant
had to be excluded from the study after the first immunization
because she needed chronic medication (i.e., Rocutan), and two
other participants dropped out of the study after the second
immunization for personal reasons, leaving seven participants in
the first recruitment group.
A second round of recruitment accrued 14 participants. Fol-
lowing the screening visit of the second group of participants, 11
women were enrolled in the study. Three women were excluded
from the study because they had HPV16 IgG titers higher than
50 (n  1), their Pap smears indicated the presence of ASCUS
(n  1), or they used an oral contraceptive other than Gynera or
Minulet (n 1). None of the 11 participants in the second group
were excluded or dropped out of the study after the start of the
immunization schedule. Therefore, a total of 18 participants
were included in this study.
The participants were then separated into two groups accord-
ing to whether they were taking oral contraceptives (the contra-
ceptive group, n  7) or not (the ovulatory group, n  11). The
ovulatory group included participants who used condoms or in-
trauterine devices for contraception or who had been sterilized
via tubal ligation. The clinical protocol for this study was ap-
proved by the local ethics committee, and written informed con-
sent was obtained from each participant after the study had been
explained to them in detail.
Vaccine and Immunization Schedule
Clinical lots of recombinant HPV16 L1 VLP vaccine, puri-
fied from insect cells and suspended in saline without adjuvant,
were provided by Novavax (Columbia, MD) and were prepared
according to good manufacturing practices guidelines, as previ-
ously described (33). Two immunization schedules were fol-
lowed. For schedule 1, participants (three women from the con-
traceptive group and four women from the ovulatory group)
received two 2-g doses of HPV16 L1 VLP vaccine at weeks 0
and 4, followed by two 50-g doses at weeks 12 and 15. For
schedule 2, participants (four women from the contraceptive
group and seven women from the ovulatory group) received two
50-g doses of HPV16 L1 VLP vaccine at weeks 0 and 4. The
stage of the menstrual or contraceptive cycle at the time of
immunization varied among the participants because no attempt
was made to standardize the timing of the immunizations.
Clinical Procedures
All participants had serum and cervical samples collected at
0 and 4 weeks after their last immunization and then twice per
week for a period of 5 weeks. For technical reasons, cervical
samples were not taken during the high-blood-flow period of
menstruation (i.e., days 25 to 28 of contraceptive cycles and
after day +13 of ovulatory cycles, with the day of ovulation
being day 0). Otherwise, cervical samples were taken at any time
during the cycles because they were considered to be physiologi-
cally relevant, even though some samples may have contained
blood. Cervical samples were collected with Weck-cell sponges
(15,24) as part of the gynecologic examination. This sampling
method has been reported to be non-traumatic (24), but we can-
not exclude the possibility that, in a few participants, bleeding
may have been induced by the examination. To avoid any pos-
sible bias introduced by the presence of blood in the samples, all
the samples containing blood (14 of 52 in the contraceptive
cycles and 13 of 48 in the ovulatory cycles) were excluded from
the statistical analysis of the ratios between cervical and serum
Journal of the National Cancer Institute, Vol. 95, No. 15, August 6, 2003 ARTICLES 1129
antibody titers in relation to the phases of the ovulatory cycle
(see Fig. 3).
To collect the cervical samples, a speculum was inserted into
the vagina and two sponges were placed sequentially in the
endocervical canal for 1 minute each. Each sponge was then
removed and placed in a 0.5-mL Eppendorf tube on ice, and 150
L of phosphate-buffered saline (PBS) containing protease in-
hibitors (pepstatin at 10 g/mL, leupeptin at 10 g/mL, antipain
at 10 g/mL, and benzamidine at 50 g/mL; all from Sigma
Chemical Co., St. Louis, MO) was added. Each tube was then
weighed, and the weight of each cervical secretion was calcu-
lated by subtracting the combined weight of an empty tube plus
a dry sponge plus 150 L of PBS. The tubes were pierced at the
bottom with a needle, placed in large 2-mL Eppendorf tubes
without lids, and centrifuged at 10 000g for 10 minutes at 4 °C.
The liquid fraction (i.e., diluted cervical secretion) was then
frozen at –70 °C until analysis. For each sample, a dilution factor
was calculated by dividing the total volume of the diluted
samples by the weight of the cervical secretion collected.
Determination of Menstrual Cycle Stage
To determine the ovulation day(s) for each participant in the
ovulatory group for the 5-week sampling period, the number of
days after (or before) menstruation was considered together with
the serum levels of estrogen, luteinizing hormone (LH), and
progesterone. Ovulation occurs approximately 36 hours after the
onset of the pre-ovulatory surge of LH. As the LH peak is
reached, estradiol levels decrease and progesterone levels con-
tinue to increase. The luteal phase begins with the expulsion of
the oocyte shortly after ovulation. Progesterone secretion gen-
erally increases to a peak 6–8 days after the LH surge. If the
oocyte is not fertilized, progesterone levels decrease until the
onset of menses. LH, estradiol, and progesterone levels were
measured in the sera of participants starting at least 9 days after
their first day of menstruation. If a clear increase in LH level was
not observed, hormone levels were determined again at the next
visit (i.e., 3–4 days later). When a clear LH peak was observed,
together with a decrease in estradiol level and an increase in
progesterone level, the day of ovulation was estimated to have
occurred 24 hours later. If the participant had a high progester-
one level (i.e., >10 ng/mL), the date of ovulation was confirmed
or determined as being 14 days before the first day of the par-
ticipant’s next menstruation.
Using these criteria, we were able to determine the ovulation
day(s) for eight of the 11 participants in the ovulatory group, two
of whom had ovulated twice during the sampling period. For the
three participants for whom we were unable to determine the
ovulation day(s), one did not appear to ovulate during the sam-
pling period (i.e., the participant had no detectable increase in
LH levels at visits occurring at days 15 and 18 of her first cycle
and days 11, 15, 18, and 23 of a second consecutive cycle), and
for the other two participants, the day of ovulation could not be
determined with enough precision. One of these participants
(who had a long cycle of 45 days) started her sampling visits 22
days after the start of menstruation and, although an intermediate
increase in LH level was observed, the precise date of ovulation
could not be determined. The second participant presented with
relatively high levels of LH at day 16 of her cycle; however,
menstruation occurred 21 days later. Relatively high levels of
LH were again measured at day 11 of her next consecutive cycle;
however, this time frame was the end of the sampling period for
that participant. One of the eight participants who had her ovu-
lation day determined and who had low HPV16 VLP serum IgG
antibody titers (i.e., 800 before cycle sampling and 200 after-
ward) had undetectable vaccine-specific IgG titers in cervical
secretions at some time points during her ovulatory cycle; there-
fore, her data were not included in the analysis of genital tract
antibodies.
For the contraceptive group, cervical secretion samples were
assigned to a particular stage of the contraceptive cycle accord-
ing to which day the contraceptive pill was taken (i.e., day 1 
first day of the 21-day packet).
Determination of Ig Levels
Ig levels were determined by enzyme-linked immunosorbent
assay (ELISA). Briefly, for determination of HPV16 VLP–spe-
cific IgG and IgA levels, Greiner 96 microtiter plates (Greiner
Bio-One, Poitiers, France) were coated with purified HPV16
VLPs (85 ng) in PBS in each well. After blocking with a solution
of PBS, 0.1% Tween, and 1% dry powdered milk for 1 hour at
37 °C, vaccine-specific Ig in both cervical and serum samples
was determined by adding biotinylated rabbit anti-human IgG
(1 : 500; Dako, Kyoto, Japan) or goat anti-human IgA (1 : 1000;
Chemicon, Temecula, CA) secondary antibodies followed by
peroxidase-conjugated streptavidin (1 : 5000; Dako) and o-phen-
ylenediamine (1 mg/mL; Sigma Chemical Co.) to each well.
Neutralizing antibody titers were not determined because a good
correlation between ELISA titers of HPV16 VLP–specific anti-
bodies and HPV16 neutralizing titers has been previously re-
ported for both serum (33,37) and genital secretions (9). For
determination of total IgG and IgA levels, Greiner 96 microtiter
plates were coated with a rabbit anti-human IgG (1 : 3000; Dako)
or a mouse monoclonal anti-human IgA (1 : 250; Zymed, San
Franciso, CA), respectively. The Ig levels in the samples were
determined as described above for the vaccine-specific Igs.
Each serum and cervical sample was tested in duplicate, with
purified human serum IgA (standard curves with eight consecu-
tive twofold dilutions starting at 102 ng/mL; Cappel, Organon
Teknika, Durham, NC) or IgG (standard curves with eight con-
secutive twofold dilutions starting at 46 ng/mL; Cappel, Orga-
non Teknika) included in the assays as reference standards. For
determination of HPV16 VLP–specific Ig levels, twofold dilu-
tions (in PBS, 0.1% Tween, and 1% dry powdered milk) of the
serum and cervical secretion samples were tested, starting at a
dilution of 1 : 50 for sera and 1 : 5 for cervical secretions. The
96-well plates were then read on an automatic plate reader (Dy-
natech Laboratories, Chantilly, VA) at a wavelength of 490 nm
and a filter of 640 nm. The variability of the duplicate assays for
each serum and cervical sample was less than 15%. When higher
variabilities were observed, each sample was tested again in
duplicate.
The titers for vaccine-specific Igs were determined as the
reciprocal end-point dilution that yielded an optical density
(OD) of more than 0.100, which corresponded to three times the
mean pre-immune OD (0.0127) plus three standard deviations
(SDs) (0.0066) for the serum dilution of 1 : 50 and two times the
mean pre-immune OD (0.0132) plus three SDs (0.0129) for the
cervical dilution of 1 : 5. These criteria have been used previ-
ously on a panel of serum samples from vaccinees (33); similar
titers were obtained in this study (data not shown). Participants
were considered to be HPV16-seropositive at recruitment if their
serum yielded an OD of more than 0.100 at a 1 : 50 dilution;
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these participants were excluded from the study, as previously
noted.
Statistical Analysis
All antibody levels are presented as geometric mean titers
(GMTs) calculated as the arithmetic mean of the log titers. Non-
parametric statistical analyses were used to determine the statis-
tical significance of differences in Ig levels between groups.
When two groups were compared, the Wilcoxon t test was used,
and when more than two groups were compared, the Kruskal–
Wallis test was used. When patterns over time within partici-
pants were evaluated (i.e., cervical-to-serum antibody ratio, total
IgGs and IgAs, and weight of secretions), unpaired rather than
paired tests were used to avoid the exclusion of results from
participants with incomplete data. When evaluating the associa-
tion of menstrual cycle stage with cervical and serum antibodies
over time, the ovulatory cycle was divided, a priori, into the
proliferative (days –11 to –6), peri-ovulatory (days –2 to +2),
and luteal phases (days +8 to +12) and the contraceptive cycle
was divided (again, a priori) into three time periods, days 4–7,
11–14, and 18–21. Mean titer levels were used whenever a par-
ticipant had more than one sample taken during a specific period
within her cycle. For example, if a participant had samples taken
twice during the luteal phase of her cycle, the mean of the two
samples was used in analyses. Correlations between antibody
titers in serum and cervical secretions were determined by the
Spearman correlation coefficient. All statistical tests were two-
sided.
RESULTS
Serum Antibody Responses to HPV Immunization
To assess the antibody response to HPV immunization, par-
ticipants received intramuscular injections of HPV16 VLPs
without adjuvant following two different immunization sched-
ules: schedule 1 consisted of two 2-g doses of HPV16 VLPs
followed by two 50-g doses, and schedule 2 consisted of two
50-g doses only. All participants, regardless of immunization
schedule, had seroconverted by 4 weeks after the last immuni-
zation; the serum anti-HPV16 VLP IgG GMTs were 4158 (95%
confidence interval [CI]  1872 to 9236) for the participants on
schedule 1 and 1925 (95% CI  1088 to 3406) for the partici-
pants on schedule 2. Because the serum anti-HPV16 VLP IgG
GMTs of the two immunization groups were not statistically
significantly different (P  .23), additional comparisons were
not stratified by the number of vaccine doses received because
the purpose of this study was to investigate the variation in
specific antibody levels at the cervix of each participant over
time independently of the serum HPV16 VLP titer reached by
each vaccine. Therefore, the rest of the results focus on com-
parisons between the ovulatory and contraceptive groups and
between different stages of the ovulatory and contraceptive
cycles within each group.
Four weeks after the last immunization, the serum GMT of
anti-HPV16 VLP IgG obtained in the contraceptive group (GMT
 3189, 95% CI  1143 to 8898) was not statistically signifi-
cantly different from the serum GMT obtained in the ovulatory
group (GMT  2278, 95% CI  1398 to 3714; P  .47). Six
weeks later, at the end of the sampling period, the GMTs for the
anti-HPV16 VLP IgGs in the contraceptive and ovulatory
groups had decreased, although not statistically significantly, to
2348 (95% CI  849 to 6491; P  .71) and 1023 (95% CI 
580 to 1802; P  .08), respectively. A similar decrease in serum
anti-HPV16 VLP IgG GMTs was also seen 2 months after the
second 50-g dose in an earlier group of participants (33).
During the sampling period, a maximal twofold variation in
the HPV16 VLP serum IgG titers was observed between two
consecutive samples (data not shown). The serum GMTs for
HPV16 VLP–specific IgA were relatively low in both groups of
participants (74 [95% CI  25 to 223] for the contraceptive
group versus 100 [95% CI  58 to 173] for the ovulatory
group), as expected from previous findings (33). Anti-HPV16
VLP–specific IgA cervical titers were also very low (maximum
titer of 40) and were often undetectable (data not shown).
HPV16 VLP–Specific Antibody Responses in Cervical
Secretions
In addition to determining the serum antibody responses to
HPV immunization, we also assessed the levels of cervical an-
tibodies in both the ovulatory and contraceptive groups. Regard-
less of immunization schedule, all participants developed cervi-
cal anti-HPV16 antibodies (Figs. 1 and 2). Therefore, we
examined possible variations in vaccine-specific cervical anti-
body levels during ovulatory and contraceptive cycles. Anti-
HPV16 VLP IgG titers during individual ovulatory cycles for
seven participants (Fig. 1, A; day 0 is the day of ovulation) were
examined, two of whom (participants E and G) had two ovula-
tions during the sampling period. Each participant’s cervical
anti-HPV VLP IgG titers were highest during the proliferative
phase, decreased an average of ninefold around ovulation, and
increased (except for participant F, whose titers remained con-
stant after ovulation), on average, threefold during the luteal
phase.
For the two participants whose day of ovulation could not be
precisely determined by serum hormone levels, the lowest cer-
vical anti-HPV VLP IgG titers were observed around 14 days
before menstruation, which was in agreement with their putative
ovulation date (data not shown). The two participants who had
cervical samples from two consecutive menstrual cycles (par-
ticipants E and G; Fig. 1, A and B) had similar antibody profiles
for both cycles. However, there was considerable variation in the
individual cervical titer curves between participants, even when
the cervical titers were normalized to each participant’s corre-
sponding serum antibody titers (Fig. 1, B).
The ratios between cervical and serum antibody titers were
also analyzed in relation to the phases of the ovulatory cycle
(Fig. 3, A). The proliferative phase had the highest ratio (median
 0.09, interquartile range [IQR]  0.04 to 0.16), the luteal
phase had an intermediate ratio (median  0.03, IQR  0.02 to
0.04), and the ovulation phase had the lowest ratio (median 
0.01, IQR  0.01 to 0.02; P  .05, compared with the prolif-
erative or luteal phases). We also examined whether there was a
correlation between cervical and serum antibody titers and found
that cervical antibody titers did not correlate with the serum
antibody titers (r  .27; Spearman correlation coefficient), sug-
gesting that there may not be a direct relationship between serum
and cervical antibody titer among participants in the ovulatory
group.
The HPV16 antibody profiles for the participants in the con-
traceptive group displayed some important differences from
those of the participants in the ovulatory group (Figs. 2 and 3).
First, the cervical anti-HPV VLP IgG titers were relatively con-
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stant throughout the contraceptive cycle—that is, there was no
variability in anti-HPV16 VLP IgG titers throughout the cycle
(Fig. 2, A and B) like there was in the ovulatory group. Inter-
estingly, the cervical titers of the one participant in the ovulatory
group who did not ovulate were also relatively constant through-
out her sampling period (data not shown). Second, when the
contraceptive cycle was divided into three phases (days 4–7,
days 11–14, and days 18–21), the cervical-to-serum antibody
ratios were not statistically significantly different, with median
ratios of 0.06 (IQR  0.05 to 0.08), 0.11 (IQR  0.06 to 0.13),
and 0.06 (IQR  0.03 to 0.13) for the three phases, respectively
(P  .71, Kruskal–Wallis test; Fig. 3, A). Third, the median
cervical-to-serum antibody ratio during the contraceptive cycle
(0.06, IQR  0.04 to 0.10; days 1–24) was statistically signifi-
cantly higher than it was in the peri-ovulatory phase (0.01, IQR
 0.01 to 0.02: days –2 to +2) (P<.001) of the ovulatory group.
Finally, although the cervical antibody titers differed among the
participants (Fig. 2), there was a correlation between the cervical
antibody titer and the serum antibody titer in the contraceptive
group (r  .86; Spearman correlation coefficient), whereas
there was no such correlation in the ovulatory group, suggesting
a direct relationship between cervical and serum antibodies
among participants in the contraceptive but not the ovulatory
group.
Total IgG and IgA Content in Cervical Secretions
To examine whether the observed relationship between serum
and cervical anti-HPV16 antibody levels might also apply to
overall antibody levels, total cervical and serum IgG and IgA
levels were determined for each participant (Fig. 3, B and C,
respectively). The median concentrations of total IgGs and IgAs
in the cervical samples during contraceptive cycles were 530
g/mL (IQR  327 to 680 g/mL) and 20.0 g/mL (IQR 
13.4 to 34.0 g/mL), respectively. The total IgG concentration
was similar to that previously reported for cervical samples col-
lected from women taking oral contraceptives (mean value ±
standard error [SE]  1169.2 ± 326.2 g/mL) (15); however,
the total IgA concentration was lower than that previously re-
ported (mean ± SE  270.1 ± 57.8 g/mL) (15). We confirmed
the low IgA concentration in our samples with a second standard
human IgA, and we also verified that our detection of IgA was
not hindered by the presence of high IgG levels by detecting
known amounts of purified IgA that were added to the cervical
secretions. Interestingly, vaginal secretions have been reported
Fig. 1. Anti-human papillomavirus 16 (HPV16)
virus-like particle (VLP) immunoglobulin G (IgG)
titers in cervical secretions during ovulatory cycles.
A) Vaccine-specific antibody titers in cervical se-
cretions from women in the ovulatory group. Each
curve represents the cervical antibody titers during
one ovulatory cycle for each of seven participants
(A–G). E and G represent the vaccine-specific an-
tibody titers during a second ovulatory cycle for par-
ticipants E and G, respectively. The mean serum
anti-HPV16 VLP IgG titers during the sampling
period are listed on the right of the figure adjacent
to each participant’s letter designation and symbol.
B) The ratio of cervical anti-HPV16 VLP antibody
titers at each time point in panel A to the serum
anti-HPV16 VLP antibody titer at the same time
point. Each curve represents the ratio during one
ovulatory cycle for participants A–G. E and G rep-
resent the ratio during the second ovulatory cycle for
participants E and G, respectively. The mean serum
anti-HPV16 VLP IgG titers during the sampling pe-
riod are listed on the right of the figure adjacent to
each participant’s letter designation.
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to have lower concentrations of IgA (mean ± SE  43.6 ± 8.3
g/mL) (15) than cervical secretions. Hence, although we
placed our Weck-cell sponges in the cervical os and efforts were
made to avoid touching the vaginal wall, we cannot exclude the
possibility that some vaginal secretions that were loosely at-
tached to the cervical mucus may have been included in our
samples, thus potentially lowering the IgA concentration.
During the contraceptive cycles, both total IgG (Fig. 3, B)
and total IgA (Fig. 3, C) concentrations were relatively constant
(P  .92 and P  .18, respectively), with median values of 485
g/mL (IQR  370 to 605 g/mL), 535 g/mL (IQR  421 to
1242 g/mL), and 460 g/mL (IQR  439 to 567 g/mL) for
IgG and 13.4 g/mL (IQR  11.0 to 25.5 g/mL), 32.8 g/mL
(IQR  27.0 to 49.0 g/mL), and 19.7 g/mL (IQR  15.0 to
28.5 g/mL) for IgA during days 4–7, 11–14, and 18–21, re-
spectively. During the ovulatory cycles, total IgG decreased sta-
tistically significantly between the proliferative phase and the
peri-ovulatory phase (from 497 g/mL, IQR  306 to 793
g/mL to 71 g/mL, IQR  49 to 114 g/mL; P  .04)
and rose again, although not statistically significantly, during
the luteal phase (to 322 g/mL, IQR  175 to 551 g/mL;
P  .11).
The variation in total IgG concentration during the ovulatory
cycles (Fig. 3, B) paralleled that observed for the vaccine-
specific IgGs (Fig. 3, A). The decrease in median total IgG
concentration from the proliferative phase to the peri-ovulatory
phase was sevenfold, which was similar to the ninefold decrease
in vaccine-specific IgG concentration. The same was also true
for the fold increase from the peri-ovulatory phase to the luteal
phase (fivefold in total IgG and threefold in specific IgG). These
results suggest that variations in HPV16 VLP–specific IgG dur-
ing ovulatory cycles are closely linked to the regulation of tran-
sudation of Igs in general and not to the vaccination procedure.
In contrast, variation in the titers of total IgA during the ovula-
tory cycle (Fig. 3, C) was not statistically significant, but the
number of participants in that group was small.
Effect of the Amount of Cervical Secretion on
Antibody Levels
To determine whether changes in the amount of cervical se-
cretion might account for the variation in antibody levels ob-
served in the cervix, we analyzed the median weight of the
cervical secretions obtained with the Weck-cell sponge during
Fig. 2. Anti-human papillomavirus 16 (HPV16) virus-like particle
(VLP) immunoglobulin G (IgG) titers in cervical secretions during
contraceptive cycles. A) Vaccine-specific antibody titers in cervi-
cal secretions from women in the contraceptive group. Each curve
represents the cervical antibody titers during one menstrual cycle
for each of seven participants (H–N). The mean serum anti-
HPV16 VLP IgG titers during the sampling period are listed on the
right of the figure adjacent to each participant’s letter designation.
B) The ratio of cervical anti-HPV16 VLP antibody titers at each
time point in panel A to the serum anti-HPV16 VLP antibody titer
at the same time point. Each curve represents the ratio during one
menstrual cycle for participants H–N. The mean serum anti-
HPV16 VLP IgG titers during the sampling period are listed on the
right of the figure adjacent to each participant’s letter designation.
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the peri-ovulatory phase and found that that phase yielded ap-
proximately two times more cervical secretions than the luteal
phase (191.3 g, IQR  141 to 250 g versus 97 g, IQR 
77 to 111 g, respectively; P  .05; Fig. 3, D). Results similar
to those in the luteal phase were found in the proliferative phase
(106.3 g, IQR  68 to 155 g; P  .91). These modest
changes in the amount of cervical secretions collected during the
different phases of the ovulatory cycle cannot, however, account
for the decrease in Ig concentration or in HPV16 VLP–specific
IgG titers seen during the peri-ovulatory phase.
DISCUSSION
Although the concentration of Igs in human cervical secre-
tions varies because of endogenous or exogenous sex hormones
(7,15,23–25,38), this is the first study, to our knowledge, in
which both total and vaccine-specific Igs have been examined
during a full menstrual cycle in ovulating women and in women
taking oral contraceptives. Our data demonstrate several impor-
tant results. First, intramuscular immunization of healthy, adult
women with HPV16 VLPs induced relatively high titers of vac-
cine-specific antibodies (mainly IgG) in cervical secretions. Sec-
ond, there was a statistically significant decrease in cervical
vaccine–specific IgG levels during ovulation. Third, the changes
in vaccine-specific IgG levels during the menstrual cycle were
quantitatively similar to those in total IgG levels. Finally, the
variation in vaccine-specific IgG levels in cervical secretions
among ovulating women was relatively independent of the an-
tibody levels induced in their serum, whereas a correlation was
observed between the vaccine-specific IgG levels in the serum
and cervical secretions among women taking oral contracep-
tives. The association of oral contraceptives with reduced
changes in cervical Ig concentration seen during the ovulatory
cycle suggests that endogenous sex hormones may be largely
responsible for regulating the antibody concentration in the fe-
male genital tract.
Because antibodies of the IgG isotype are predominant in
female genital-tract secretions and are largely of plasma origin,
it has been assumed that systemic immunization may be an
effective route of immunization for inducing humoral immune
responses in cervico-vaginal secretions. Indeed, this response
was observed after intramuscular vaccination with a tetanus vac-
cine (consisting of purified tetanus toxoid) administered with
aluminum hydroxide (14). However, systemic immunization
with a vaccine consisting of inactivated influenza virus did not
lead to the detection of vaccine-specific IgGs in genital secre-
tions (15), suggesting that cervical antibody response may de-
pend on the type of vaccine used, the immunization schedule,
and/or other unknown parameters.
There were several important differences in the cervical an-
tibody profiles between the participants in the contraceptive and
ovulatory groups. The vaccine-specific Ig titers in the cervical
secretions of women in the contraceptive group were relatively
stable. The same was also true for total Igs, which is in agree-
ment with previous findings (15). However, there was a statis-
tically significant variation in both vaccine-specific and total Igs
during the ovulatory cycles, with the lowest levels of antibodies
occurring around ovulation. Franklin and Kutteh (25) reported a
fourfold difference between the pre-ovulatory and peri-
ovulatory levels of total IgG and IgA during a 9-day evaluation
of cervical antibody levels around ovulation (days –4 to + 4).
Our total IgG results, which have confirmed and extended these
observations to a full menstrual cycle and include vaccine-
specific antibody responses to systemic immunization, show an
even greater difference (approximately seven- to ninefold) in
median IgG levels between the proliferative and peri-ovulatory
phases. Interestingly, we measured only a twofold difference in
the amount of cervical secretion collected by our Weck-cell
procedure between the proliferative and peri-ovulatory phases.
Therefore, the increased amount of cervical secretions in the
peri-ovulatory phase can only partially account for the much
larger decrease in Ig concentration during that phase. Although
it is possible that our collection procedure may not reflect the
total volume of cervical secretions, our results do raise the pos-
sibility that there may be hormone-dependent changes in the
efficiency with which Igs are transudated or produced in the
female genital tract. The mechanisms of transudation or diffu-
sion through the mucosa are poorly understood and deserve
further investigation. Active transport of IgG through the genital
mucosa by an Fc receptor–associated mechanism (8) and local
production of IgG (15) have been proposed to contribute to
transudation or diffusion, and both of these mechanisms could
be influenced by sex hormones, as has been demonstrated for the
local production of sIgA (16–18,39).
Our finding that HPV16 VLP–specific IgGs are induced in
the cervical secretions of all participants is consistent with the
encouraging results of protection against HPV16 infection that
were recently reported in women immunized with an HPV16
VLP vaccine (36). The vast majority of women in that trial (36)
were taking oral contraceptives, which we have found to be
associated with constant and high levels of vaccine-specific an-
tibodies. Given our observation that ovulating women have
much lower HPV16 VLP–specific antibody titers around ovula-
tion than at other times in the menstrual cycle, it will be impor-
tant to determine whether the HPV16 VLP vaccine will be as
effective at protecting ovulating women from HPV16 infections
as it appears to be for women taking oral contraceptives.
The decrease in vaccine-specific antibody concentration
around ovulation might represent a protective mechanism that
reduces the level of anti-sperm antibodies in the female genital
tract at a time when conception is most likely to occur. It is also
possible that the decrease in vaccine-specific antibody concen-
tration around ovulation may predispose ovulating women to be
more susceptible to some genital infections than both non-
ovulating women and women taking oral contraceptives. To our
Fig. 3. Comparison of cervical antibody levels during ovulatory cycles versus
oral contraceptive cycles. Comparisons were made by treating each data point as
an independent observation in the contraceptive group (days 1–24) and as mean
levels whenever a woman had more than one sample taken during a specific
stage during her cycle. Only cervical samples that did not contain blood have
been included in this analysis. Horizontal bars represent the median values of
the indicated parameter at each phase of the contraceptive and ovulatory cycles.
A) Level of anti-human papillomavirus 16 (HPV16) virus-like particle (VLP)
immunoglobulin G (IgG) titers in cervical secretions. The vertical axis repre-
sents the ratio of cervical anti-HPV16 VLP antibody titers to the serum anti-
HPV16 VLP antibody titer for each participant. The horizontal axis represents
the data for the individual determinations shown in Fig. 1, B, for the ovulatory
cycles and Fig. 2, B, for the contraceptive cycles. B) Level of total IgG in
cervical secretions. C) Level of total IgA in cervical secretions. D) Weight of
cervical secretions. For panels A, B, C, and D, the horizontal axis represents the
data for the individuals shown in Fig. 1, B, for the ovulatory cycles and Fig. 2,
B, for the contraceptive cycles during the a priori arbitrarily defined periods of
the cycle indicated below each horizontal axis.
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knowledge, a higher susceptibility to sexually transmitted dis-
ease during ovulation has not been reported, but it is unclear
whether this issue has been directly evaluated. Susceptibility to
gonococcal infection has, however, been reported to be lower at
mid-cycle because of higher antigonococcal serum activity, sec-
ondary to increased complement hemolytic activity during ovu-
lation (40), suggesting that other immune effectors may coun-
terbalance the lower antibody concentration in the female genital
tract around ovulation. Furthermore, higher susceptibility to
chlamydial cervicitis has been associated with oral contraception
(41), although chlamydial pelvic inflammatory disease was de-
creased in women using oral contraceptives (42).
Among ovulating women, the cervical vaccine–specific anti-
body concentrations appeared to be only weakly correlated with
the serum-specific antibody concentrations. This finding sug-
gests that the measurement of cervical antibody levels, in addi-
tion to serum antibody levels, might provide insight into vaccine
failures and the clinical importance of vaccine-induced antibod-
ies in cervical secretions. The latter issue is difficult to address
experimentally because there is no animal model in which the
sexual transmission of PV to the cervix can be readily tested.
Our finding of a wide variation in cervical antibody levels dur-
ing the ovulatory cycle suggests that it is essential to know when
during the cycle a cervical sample has been taken; it appears that
the most relevant time to collect cervical samples is when the
antibody levels are lowest, i.e., during the peri-ovulatory phase.
In summary, we have shown that a candidate HPV vaccine,
HPV16 VLP, has the desirable property of inducing vaccine-
specific antibodies in cervical secretions in healthy, adult
women, thus placing the antibodies at the site where protection
is needed. It remains unclear, however, whether the observed
decrease in HPV16 VLP–specific antibodies during ovulation
may jeopardize the efficacy of this vaccine. In this regard, it may
be worthwhile to evaluate alternative (e.g., mucosal) routes of
immunization that can induce local production of specific anti-
bodies, as has been demonstrated in a mouse model (9).
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